On Friday, BridgeBio Pharma Inc (NASDAQ: BBIO) opened lower -0.94% from the last session, before settling in for the closing price of $34.11. Price fluctuations for BBIO have ranged from $21.62 to $41.04 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 147.21%. Company’s average yearly earnings per share was noted 36.14% at the time writing. With a float of $147.77 million, this company’s outstanding shares have now reached $188.99 million.
Let’s determine the extent of company efficiency that accounts for 550 employees. In terms of profitability, gross margin is 98.31%, operating margin of -248.42%, and the pretax margin is -204.94%.
BridgeBio Pharma Inc (BBIO) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BridgeBio Pharma Inc is 21.81%, while institutional ownership is 75.80%. The most recent insider transaction that took place on Nov 19 ’24, was worth 613,826. In this transaction Chief Executive Officer of this company sold 27,389 shares at a rate of $22.41, taking the stock ownership to the 4,897,443 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Secretary, Treasurer & CFO sold 4,156 for $22.41, making the entire transaction worth $93,137. This insider now owns 93,758 shares in total.
BridgeBio Pharma Inc (BBIO) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 36.14% per share during the next fiscal year.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Check out the current performance indicators for BridgeBio Pharma Inc (BBIO). In the past quarter, the stock posted a quick ratio of 3.19. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.41, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -3.56 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Looking closely at BridgeBio Pharma Inc (NASDAQ: BBIO), its last 5-days average volume was 5.52 million, which is a jump from its year-to-date volume of 3.34 million. As of the previous 9 days, the stock’s Stochastic %D was 77.11%. Additionally, its Average True Range was 1.58.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 83.13%, which indicates a significant increase from 72.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.49% in the past 14 days, which was higher than the 60.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.49, while its 200-day Moving Average is $26.71. However, in the short run, BridgeBio Pharma Inc’s stock first resistance to watch stands at $34.54. Second resistance stands at $35.29. The third major resistance level sits at $35.68. If the price goes on to break the first support level at $33.40, it is likely to go to the next support level at $33.01. Now, if the price goes above the second support level, the third support stands at $32.26.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
There are currently 188,990K shares outstanding in the company with a market cap of 6.39 billion. Presently, the company’s annual sales total 9,300 K according to its annual income of -643,200 K. Last quarter, the company’s sales amounted to 2,730 K and its income totaled -162,040 K.
